Plain-English translation of NCT06617858 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Colorectal Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called for people with colorectal cancer who have completed their standard treatments (like surgery or chemotherapy) but still have traces of cancer detected in a blood test. Researchers want to see if this medication can clear those cancer traces and help prevent the cancer from coming back.
Even after successful colorectal cancer treatment, some patients have tiny amounts of cancer cells that show up in blood tests. This medication is being studied to see if it can eliminate these remaining traces and improve long-term outcomes for these patients.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would receive the medication for six months, likely through regular clinic visits at M.D. Anderson Cancer Center. During this time, you'll have blood tests to check how well the medication is working, monitor for side effects, and assess your organ function. After six months of treatment, researchers will follow your health for two years to see if the medication helped prevent cancer recurrence.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
M.D. Anderson Cancer Center
Enrollment target
~15 participants
Started
December 2024
Primary completion
February 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Van Morris, MD
M.D. Anderson Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.